Rhéoflux

Rhéoflux is an approved cardiovascular medication containing the small molecule flavonoid derivative troxerutin. Developed and marketed by Ethyx Pharmaceuticals, it is classified as a venotonic and vasculoprotective agent. The drug is primarily indicated for the treatment of chronic venous insufficiency (CVI) and the management of hemorrhoidal crises. Rhéoflux works by increasing the tone of venous walls and strengthening small blood vessels (capillaries), which helps to reduce edema and improve microcirculatory blood flow. In France, it is available in high-dose oral formulations, specifically as a 3500 mg powder for drinkable solution in sachets and a 3500 mg/7ml drinkable solution in ampoules. Ethyx Pharmaceuticals acquired this mature medication as part of its business model focused on commercializing established pharmaceutical products.

Brand names

Rhéoflux

Other names

troxerutintroxérutine